Skip to main content

Table 1 Study endpoints based on symptoms

From: Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold

End point

Carrageenan nasal spray n = 14

Placebo nasal spray n = 18

p-value

Primary endpoint

   

TSS mean of sum on days 2-4

4.62 ± 2,06

6.28 ± 2.29

0.046

Secondary endpoints

   

LSS mean of sum on days 2-4

3.79 ± 2,03

5.22 ± 2.30

0.068

SSS mean of sum on days 2-4

0.83 ± 0,75

1.06 ± 1,07

0.704

  1. Shown are symptom scores TSS (total symptom score), LSS (local symptom score), and SSS (systemic symptom score) ± standard deviation.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us